LSK Global PS Becomes First Korean Partner to Achieve Medidata Solutions Accreditation

LSK Global PS Becomes First Korean Partner to Achieve Medidata Solutions Accreditation

Leading Korean CRO Provides Global Sponsor Customers with Full Suite of Services Around Medidata Rave 

NEW YORK, Jun 25, 2012 -- Contract research organization (CRO) LSK Global PS has strengthened its partnership with Medidata Solutions MDSO -1.51% by becoming the first Korean partner to attain accreditation in the Medidata Partner Program. By becoming accredited in the Medidata Rave(R) electronic data capture (EDC) and clinical data management (CDM) system, LSK can provide a full suite of Rave services to the growing South Korea trial market as well as global sponsors.

-- "With the strong local support of the Medidata team over the past year, we have increased our ability to successfully provide high-quality services for our sponsor customers," said Young-Jack Lee, president, LSK. "Medidata's global reputation and experience in emerging markets has proven invaluable as Korean pharmas evolve their processes to adhere to new local laws and varying regulations around the world."

As sponsors in the Korean market continue to expand globally, LSK found value in extending its relationship with Medidata around Rave's easy-to-use platform and streamlined processes. The new accreditation enables LSK to serve as a single source for sponsors to acquire all Rave-related services, including end user training, study build, reporting, outputs, integrations and migrations.

-- "With this accreditation, LSK continues to demonstrate its commitment to providing sponsors with increasing efficiencies across their clinical trials and expertise around both local and global regulations," said Tarek Sherif, CEO, Medidata Solutions. "This achievement further highlights Medidata's expanding global reach, particularly in the growing Asian market."

Medidata first announced its channel partner program in April 2005 to enable select CROs and other service providers to offer Medidata Rave implementation services. Since then, the program has grown to include more than 30 partners in the U.S., Europe and Asia, ranging from smaller clinical consultancies to large, global CROs and now offers accreditations for eight Medidata applications in its cloud-based clinical platform.

Connect with Medidata:

-- Read our blog, Geeks Talk Clinical

-- Tweet this: LSK Global PS (@KoreaCRO_LSK) becomes first Korean partner to achieve @Medidata Rave accreditation http://bit.ly/MPjs8J #clinical

-- Follow us on Twitter: @Medidata

-- Find us on LinkedIn

About LSK Global PS

LSK Global PS is a Korean full service CRO in Seoul. LSK Global PS has been in business since March 2000, and has a vision of opening the door to the world market for Korean medical products. We have an office in Seoul and partners all over the world, actively promoting clinical trials in Korea and clinical trials of Korean products abroad. LSK Global PS will continue to strengthen its capabilities and exercise its leadership in the clinical trial community of Korea and beyond.

About Medidata Solutions Worldwide

Medidata Solutions is a leading global provider of cloud-based clinical development solutions that enhance the efficiency of customers' clinical trials. Medidata's advanced platform lowers the total cost of clinical development by optimizing clinical trials from concept to conclusion: from study and protocol design, trial planning and budgeting, site negotiation, clinical portal, trial management, randomization and trial supply management, clinical data capture and management, safety events capture, medical coding to business analytics. Our diverse life science customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics.

SOURCE: Medidata


       
        Lois Paul and Partners
        Susan McCarron, 617-986-5767
        [email protected]
      

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

WCG is continuing its buyout run after acquiring clinical trial solutions firm Trifecta Clinical.

London-based uMed has raised nearly $4.8 million from U.K. and U.S. VCs to help healthcare providers participate in more clinical studies.

Amgen has teamed up with cloud-based trial solutions firm Reify Health to help boost patients into its drug studies.